Drugs News and Research

RSS

Longer looks: The frustrations of academic medicine; Small business owners fear health law changes; A doctor struggles to save his mother

Like many franchisees, Robert U. Mayfield, who owns five Dairy Queens in and around Austin, Tex., is always eager to expand and - no surprise - has had his eyes on opening a sixth DQ. But he said concerns about the new federal health care law had persuaded him to hold off.

7 Dec 2012

Roundup: Fla. judge rules legislature must decide on prison care privatization; Skepticism over Ore. medical liability reform proposal

A Tallahassee judge ruled Tuesday that a legislative committee did not have the authority to approve a contract regarding prison health care services. According to Businessweek, the plan would privatize health care services in three of Florida's four prison system regions. Circuit Judge John Cooper, who made the decision, said the policy changes must be approved by the full Legislature, rather than just a panel of 14 select legislators.

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Bilirubin can inhibit clogging of arteries and prevent deadly consequences

Each year, about 610,000 Americans suffer their first heart attack, according to the Centers for Disease Control and Prevention. Heart attacks and other symptoms of cardiovascular disease can be caused when blockage occurs in the arteries. In a new study from the University of Missouri, a scientist has discovered a natural defense against arterial blockage: bilirubin.

6 Dec 2012

Bio-Path to initiate BP-100-1.01 Phase I trial for treatment of two types of breast cancer

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

6 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

Study catalogs genetic variation of microbes that live in the gut

Our bodies contain far more microbial genes than human genes. And a new study suggests that just as human DNA varies from person to person, so too does the massive collection of microbial DNA in the intestine.

6 Dec 2012

Fexinidazole enters Phase II/III clinical study to treat sleeping sickness

A new oral-only treatment for sleeping sickness has entered Phase II/III clinical study in patients with late-stage sleeping sickness in the Democratic Republic of the Congo (DRC) and soon in Central African Republic (CAR).

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

Bisphenol A blocks calcium channels in cell membranes

Bisphenol A, a substance found in many synthetic products, is considered to be harmful, particularly, for fetuses and babies. Researchers from the University of Bonn have now shown in experiments on cells from human and mouse tissue that this environmental chemical blocks calcium channels in cell membranes. Similar effects are elicited by drugs used to treat high blood pressure and cardiac arrhythmia. The results are now presented in the journal "Molecular Pharmacology."

6 Dec 2012

Investigators describe process by which apoE4 protein promotes development of Alzheimer's

Despite researchers' best efforts, no drug exists that can slow, halt or reverse the onslaught of Alzheimer's disease. A progressive and fatal neurodegenerative disorder, Alzheimer's has stolen the memories and livelihoods of millions-leaving patients and their families struggling to cope with the disease's devastating consequences. But today, scientists at the Gladstone Institutes propose a new research avenue that has the potential to change all that.

6 Dec 2012

Global Post examines unproven, unscientific HIV treatments

Global Post examines how "many HIV patients around the world continue to turn to more affordable but far less reliable treatments" instead of proven -- but more expensive -- therapies, such as antiretroviral (ARV) drugs.

6 Dec 2012

Government announces fraud collections hit record $5 billion

The Justice Department's civil division recovered a record $5 billion in the past fiscal year from companies that defrauded taxpayers, with much of the abuse occurring in the health care and mortgage industries.

6 Dec 2012

Studies gauge health law's impact on consumer savings, Rx drug coverage

The Commonwealth Fund concluded that consumers saved $1.5 billion in 2011 as a result of a provision that limits how much insurers can spend on expenses not related to medical care. Meanwhile, Avalere Health found that drug coverage plans offered on health exchanges will vary by state.

6 Dec 2012

Poorer cancer patients less likely to have access to experimental drug trials

Among people with advanced cancer, poorer patients are less likely to be referred for clinical trials of experimental drugs, a new study from the UK suggests.

6 Dec 2012

No serious complications of regional nerve blocks in children

A review of more than 15,000 nerve block procedures performed in children at U.S. hospitals finds little or no risk of permanent complications or death, reports a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Synthetic marijuana linked to 11,406 of 4.9M drug-related ED visits in 2010

Street forms of synthetic cannabinoids - so-called "synthetic marijuana" - were linked to 11,406 of the 4.9 million drug-related emergency department (ED) visits in 2010, according to a new report by the Substance Abuse and Mental Health Services Administration (SAMHSA).

6 Dec 2012

Prescribing opioids lead to admissions for substance abuse treatment and deaths

A Viewpoint article published recently in the Journal of the American Medical Association suggests that the clinical practice of prescribing amphetamines, opioids, and benzodiazepines to treat chronic pain may be contributing to the increase in fatal drug overdoses and the likelihood that those drugs will be diverted to the illegal market.

6 Dec 2012

ASU scientists use X-ray laser to reveal 3-D structure of cathepsin B enzyme

An international team of scientists, using the world's most powerful X-ray laser, has revealed the three dimensional structure of a key enzyme that enables the single-celled parasite that causes African trypanosomiasis (or sleeping sickness) in humans.

6 Dec 2012